189 related articles for article (PubMed ID: 24328486)
1. Aquagenic wrinkling of the palms in a patient with cystic fibrosis.
Grasemann H; Ratjen F; Solomon M
N Engl J Med; 2013 Dec; 369(24):2362-3. PubMed ID: 24328486
[No Abstract] [Full Text] [Related]
2. Aquagenic wrinkling of the palms in cystic fibrosis patients treated with ivacaftor.
Jacobi E; Solomon M; Avolio J; Shaw M; Gonska T; Ratjen F; Grasemann H
J Cyst Fibros; 2022 Mar; 21(2):e102-e105. PubMed ID: 35063397
[TBL] [Abstract][Full Text] [Related]
3. Ivacaftor in a G551D homozygote with cystic fibrosis.
Harrison MJ; Murphy DM; Plant BJ
N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
[No Abstract] [Full Text] [Related]
4. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
5. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
6. PharmGKB summary: very important pharmacogene information for CFTR.
McDonagh EM; Clancy JP; Altman RB; Klein TE
Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096
[No Abstract] [Full Text] [Related]
7. Pulmonology: CFTR modulators for cystic fibrosis.
Bertoncini E; Colomb-Lippa D
JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
[No Abstract] [Full Text] [Related]
8. High prevalence of aquagenic wrinkling of the palms in patients with cystic fibrosis and association with measurable increases in transepidermal water loss.
Arkin LM; Flory JH; Shin DB; Gelfand JM; Treat JR; Allen J; Rubenstein RC; Yan AC
Pediatr Dermatol; 2012; 29(5):560-6. PubMed ID: 22471628
[TBL] [Abstract][Full Text] [Related]
9. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
Seliger VI; Rodman D; Van Goor F; Schmelz A; Mueller P
J Cyst Fibros; 2013 Dec; 12(6):706-13. PubMed ID: 23628510
[TBL] [Abstract][Full Text] [Related]
10. Aquagenic wrinkling of the palms in patients with cystic fibrosis.
Kaiser H; Brustad N; Pressler T; Bygum A
Br J Dermatol; 2018 Aug; 179(2):494-495. PubMed ID: 29451691
[No Abstract] [Full Text] [Related]
11. [Aquagenic wrinkling of the palms in a patient with cystic fibrosis heterozygous for the DeltaF 508 mutation].
Garçon N; Roguedas AM; Misery L; Audrezet MP; Ferec C
Ann Dermatol Venereol; 2008 Mar; 135(3):232-4. PubMed ID: 18374861
[No Abstract] [Full Text] [Related]
12. Ivacaftor.
Davis PB; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Apr; 11(5):349-50. PubMed ID: 22543461
[No Abstract] [Full Text] [Related]
13. Aquagenic wrinkling of the palms in cystic fibrosis and the cystic fibrosis carrier state: a case–control study.
Gild R; Clay CD; Morey S
Br J Dermatol; 2010 Nov; 163(5):1082-4. PubMed ID: 20560957
[TBL] [Abstract][Full Text] [Related]
14. First cystic fibrosis drug advances towards approval.
Sheridan C
Nat Biotechnol; 2011 Jun; 29(6):465-6. PubMed ID: 21654649
[No Abstract] [Full Text] [Related]
15. CFTR potentiators: not an open and shut case.
Clancy JP
Sci Transl Med; 2014 Jul; 6(246):246fs27. PubMed ID: 25101884
[TBL] [Abstract][Full Text] [Related]
16. Understanding the relationship between sweat chloride and lung function in cystic fibrosis.
Heltshe SL; Mayer-Hamblett N; Rowe SM
Chest; 2013 Oct; 144(4):1418. PubMed ID: 24081360
[No Abstract] [Full Text] [Related]
17. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
18. Response.
Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
Chest; 2013 Oct; 144(4):1418-1419. PubMed ID: 24081359
[No Abstract] [Full Text] [Related]
19. Radical new treatments for cystic fibrosis.
Arch Dis Child; 2015 Aug; 100(8):727. PubMed ID: 26078470
[No Abstract] [Full Text] [Related]
20. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Brewington JJ; McPhail GL; Clancy JP
Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
